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KEYWORDS	
	 Novel	 3,4,5‐substituted‐oxazolidin‐2‐ones	 containing	 piperazine,	 1‐(4‐chlorophenyl)
piperazine,	 benzhydrylpiperazine,	 morpholine	 and	 piperidine	 rings	 were	 synthesized	 via
Mannich	 reaction.	 The	 stereochemistry	 of	 syn	 and	 anti‐isomers	 was	 assigned	 using	 the
observed	differences	in	the	chemical	shifts	of	the	oxazolidinone	ring	protons	and	the	values	of
vicinal	 coupling	constants	 (3J)	between	 the	 two	protons	of	 the	oxazolidin‐2‐one	ring.	For	all
compounds	NOE	(Nuclear	Overhauser	Effect)	NMR	spectra	were	measured	in	order	to	prove
additionally	 the	 position	 of	 the	 substituents	 in	 the	 oxazolidin‐2‐one	 ring.	 Some	 physic
chemical,	 steric	 and	 electronic	 properties	 of	 the	 compounds	 were	 determined	 in	 order	 to
establish	 the	 similarity	 between	 the	 synthesized	 and	 reference	 compounds.	 The	 performed
computations	 showed	 that	 the	 anti‐isomers	 possessed	 lower	 electronic	 energies	 in
comparison	to	these	of	syn‐compounds.	The	nucleus‐nucleus	repulse	energies	(NRE)	and	the
highest	occupied	molecular	orbital	energies	(HOMO)	of	 the	anti‐isomers	are	higher	than	the
HOMO	 and	 NRE	 energies	 of	 syn‐compounds.	 The	 Connolly	 Solvent	 Accessible	 Surface	 Area
(SAS)	and	Connolly	Molecular	Surface	Area	(MS)	values	of	anti‐isomers	are	lower	than	these
of	syn‐isomers.	The	same	relations	were	observed	for	the	reference	compounds.	Probably	the
differences	in	the	electronic	and	steric	properties	are	responsible	not	only	for	the	higher	LD50
value	 of	 the	 reference	anti‐compound,	 but	 also	may	 contribute	 to	 the	higher	 toxicity	 of	 the
prepared	anti‐Mannich	bases	in	comparison	to	that	of	the	syn‐diastereoisomers.	
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1.	Introduction	
	
The	 oxazolidin‐2‐ones	 are	 an	 important	 class	 of	
heterocyclic	 compounds,	 which	 attract	 the	 attention	 of	 the	
investigators	 with	 the	 possibilities	 they	 give	 both	 for	 total	
regio‐	and	stereocontrol	 in	 the	synthesis	of	 “enantiomerically‐
pure”	 compounds	 like	 β‐hydroxy‐carboxylic	 acids,	 amino	
alcohols,	 aminophosphonic	 acids	 and	 for	 the	 modifying	 of	
complicated	 structures	 of	 natural	 origin	 [1‐5].	 Moreover,	
oxazolidin‐2‐one	 derivatives	 are	 particularly	 versatile	 drugs	
and	 their	 study	 is	 extremely	 relevant	 from	 a	 pharmacological	
point	 of	 view.	 The	 oxazolidin‐2‐one	 compounds	 represent	 a	
new	class	of	 antibacterial	 agents,	 effective	against	virtually	 all	
important	 gram‐positive	 pathogens,	 including	 methicillin‐
resistant	 staphylococci,	 penicillin‐resistant	 pneumococci,	
macrolide‐resistant	 streptococci	 and	 vancomycin‐resistant	
enterococci.	 The	 pharmacokinetic	 traits	 of	 linezolid	 and	
eperozolid	 encouraged	 the	 further	 investigation	 for	
improvement	 of	 the	 characteristics	 of	 the	 oxazolidinones	 in	
order	 to	 eliminate	 the	 early	 resistance	 development	 [6‐9].	
Depending	on	the	placement	of	 the	substituents,	oxazolidin‐2‐
one	 derivatives	 exhibit	 different	 activity.	 The	 3‐phenyl‐
oxazolidin‐2‐one	 derivatives	 substituted	 at	 position	 5	 with	
alcoholic	 or	 ethereal	 group	 as	 toloxatone,	 cimoxatone	 are	
proved	 to	 be	 anti‐depressant	 agents,	 while	 the	 5‐amino‐3‐
phenyloxazolidin‐2‐one	 derivatives	 are	 effective	 as	 anti‐
Parkinson	 agents	 (almoxatone,	 MD	 780236)	 [10‐12].	 Some	
oxazolidin‐2‐ones	 are	 useful	 as	 selective	 alpha‐7	 nicotinic	
receptor	 agonist,	 as	 centrally	 acting	muscarinic	 agents	 and	 as	
analgesic	 agents	 for	 the	 treatment	 of	 pain,	 as	 sleep	 aids	 and	
agents	 for	 treating	 the	 symptoms	 of	 senile	 dementia,	
Alzheimer's	disease	[13‐15].	
In	 this	 paper,	 we	 describe	 the	 synthesis	 of	 some	 novel	
3,4,5‐trisubstituted‐oxazolidin‐2‐ones	 containing	 piperazine,	
benzhydrylpiperazine,	 morpholine	 and	 piperidine	 rings	 via	
Mannich	 reaction	 as	 potential	 bioactive	 compound	 as	 well	 as	
some	of	their	physicochemical,	steric	and		electronic	properties	
in	 order	 to	 estimate	 the	 similarity	 between	 these	 new	
oxazolidinones	 and	 our	 previously	 reported.	 The	 latter	
compounds	 were	 found	 to	 possess	 analgesic	 activity	 against	
acetic	 acid‐induced	 pain,	 but	 different	 LD50	 values	 [16].	 The	
present	paper	is	a	continuation	of	this	work	and	is	focused	on	
understanding	 in	more	depth	 the	physical	properties	of	3,4,5‐
substituted	 oxazolidin‐2‐ones	 as	 a	 function	 of	 their	 ring	
stereochemistry.	
The	 selection	 of	 these	 structures	 used	 in	 this	 study	 was	
done	in	accordance	with	the	fact	that	the	thiophene	heterocycle	
takes	 part	 in	 the	 structure	 of	 some	 substances,	 possessing	
analgesic	 activity,	 and	 the	 piperazine,	 morpholine	 and	
piperidine	 moieties	 occur	 as	 a	 pharmacophore	 in	 many	
biological	active	compounds	and	are	essential	elements	in	drug	
design	[17‐21].	
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2.	Experimental	
	
Melting	 points	were	 determined	 on	 an	 Electrothermal	 AZ	
9000	 3MK4	 apparatus	 and	 were	 uncorrected.	 The	 thin	 layer	
chromatography	 (TLC,	Rf	 values)	was	 performed	 on	 silica	 gel	
60	 plates	 F254	 and	 Al2O3‐plates	 (Merck,	 0.2	 mm	 thick)	 using	
mobile	 phase	 benzene:diethyl	 ether	 (1:1;),	 benzene:diethyl	
ether:ethanol	(4:1:3;	4:1:2)	and	visualization	was	effected	with	
ultraviolet	light.	IR	spectra	were	recorded	on	a	Bruker	Equinox	
55	 spectrophotometer	 as	 potassium	 bromide	 discs.	 1H	 NMR	
spectra	 were	 obtained	 on	 a	 Bruker	 Avance	 DRX	 250	 MHz	
spectrometer	 (Bruker,	 Faelanden,	 Switzerland)	using	 a	 dual	 5	
mm	probe	head	and	CDCl3	and	DMSO‐d6	as	solvents.	Chemical	
shifts	were	expressed	 relative	 to	 tetramethylsilane	 (TMS)	and	
were	reported	as	δ	(ppm).	The	measurements	were	carried	out	
at	ambient	temperature	(300	K).	Typical	conditions	for	1‐D	1H	
spectra	 were:	 pulse	 width	 30°,	 FT	 size	 32	 K	 and	 digital	
resolution	0.2	Hz	per	point.	
	
2.	Synthesis		
	
Compounds	 1,	 2	 and	 3	 were	 prepared	 according	 the	
procedure	reported	in	[22].		
	
2.1.	General	procedure	for	compounds	4	and	6	
	
A	 three‐necked	 flask	 equipped	 with	 a	 stirrer,	 condenser	
and	 thermometer	 was	 charged	with	 0.05	mol	 (2S,3R)	 or	 (2R,	
3R)‐2‐methyl‐3‐(thien‐2‐yl)‐3‐hydroxypropanoyl	hydrazide	(	2	
or	3),	 solution	of	3.2	mL	acetic	acid	 in	100	mL	water	and	120	
mL	diethyl	ether.	To	the	formed	suspension	a	solution	of	3.8	g	
sodium	nitrite	in	30	mL	water	was	added	drop	wise	at	15‐20	°C	
by	stirring	for	20	minutes.	The	reaction	mixture	was	stirred	at	
the	above	mentioned	temperature	up	to	the	full	disappearance	
of	the	solid	phase,	about	2	or	3	hours.	After	neutralization	with	
10%	solution	of	 sodium	hydrogen	carbonate	 the	aqueous	and	
organic	 layers	 were	 separated.	 The	 aqueous	 layer	 was	
extracted	 several	 times	 with	 benzene	 and	 diethyl	 ether.	 The	
collected	organic	 layers	were	dried	with	 sodium	sulphate	and	
after	 filtering	 the	 solution	 was	 concentrated	 under	 reduced	
pressure	 to	 20‐25	 mL	 of	 the	 original	 volume.	 4‐Methyl‐5‐
(thien‐2‐yl)‐oxazolidine‐2‐ones,	(4,	6)	crystallized	after	cooling	
of	 the	 remained	 residue.	 The	 compounds	were	 re‐crystallized	
with	benzene.	
Anti‐4‐methyl‐5‐thien‐2‐yl‐1,3‐oxazolidin‐2‐one,	4:	 Yield:	 70	
%.	 M.p.:	 87‐90	 °C.	 Rf	 =	 0.66,	 mobile	 phase:	 benzene:diethyl	
ether	 (1:1).	 1H	NMR	 (CDCl3):	 1.33	 (3H,	 CH3,	 d,	 J=6.2	Hz);	 3.98	
(1H,	N‐CH,	dq,	 J=7.7,	 J=6.2	Hz);	5.16	 (1H,	OCH,	d,	 J=7.7),	6.66‐
6.64	 (2H,	 2CH,	 m,	 thiophene),	 6.92	 (1H,	 CH,	 d,	 J=4.5	 Hz,	
thiophene).	 13C	 NMR	 (CDCl3):	 15.4	 (CH3),	 56.5	 (NCH),	 81.5	
(OCH),	 125.0,	 126.0,	 127.2	 (3CH,	 thiophene),	 136.8,	 137.2	 (C,	
thiophene);	158.7	(C=O).	Anal.	Calcd.	for	C8H9NO2S:	C,	52.44;	H,	
4.95;	 N,	 7.64;	 S,	 17.50;	 Found:	 C,	 52.40;	 H,	 4.91;	 N,	 7.69;	 S,	
17.46.	
Syn‐4‐methyl‐5‐thien‐2‐yl‐1,3‐oxazolidin‐2‐one,	 6:	 Yield:	
65%.	M.p.:	101‐102	°C.	Rf	=	0.50,	mobile	phase:	benzene:diethyl	
ether	 (1:1),	 Al2O3‐plates.	 1H	 NMR	 (CDCl3):	 0.99	 (3H,	 CH3,	 d,	
J=6.60	Hz);	4.22	(1H,	N‐CH,	dq,	J=8.07	Hz,	J=6.60	Hz),	5.91	(1H,	
OCH,	 d,	 J=8.07	Hz),	 6.54	 (1H,	NH,	 bs),	 7.10–6.99	 (2H,	 2CH,	m,	
thiophene),	7.34	(1H,	CH,	dd,	J=1.71	Hz,	J=4.52	Hz,	thiophene).	
13C	 NMR	 (CDCl3):	 16.8	 (CH3),	 52.5	 (NCH),	 78.1	 (OCH),	 125.8,	
126.0,	 126.8	 (3CH,	 thiophene),	 137.2	 (C,	 thiophene),	 159.1	
(C=O).	Anal.	 Calcd.	 for	C8H9NO2S:	 C,	 52.44;	H,	 4.95;	N,	 7.64;	 S,	
17.50;	Found:	C,	52.38;	H,	5.05;	N,	7.60;	S,	17.37.	
	
2.2.	General	procedure	for	compounds	5e	and	7e	
	
To	 a	 solution	 of	 1	 g	 (5.5	 mmol)	 of	 the	 anti‐4‐methyl‐5‐
thien‐2‐yl‐1,3‐oxazolidin‐2‐one	 4	 or	 to	 a	 solution	 of	 1	 g	 (5.5	
mmol)	of	the	syn‐isomer	6	in	40	mL	ethanol	were	added	0.53	g	
(2.7	 mmol)	 piperazine	 hexahydrate	 and	 0.54	 mL	 (6.8	 mmol)	
formaldehyde	in	form	of	35%.	The	solution	was	refluxed	for	2	
hours	and	after	that	ethanol	was	distilled	in	vacuum	to	5‐10	mL	
of	 original	 volume.	 The	 obtained	 Mannich	 base	 crystallized	
upon	cooling	and	was	re‐crystallized	with	ethanol.		
Anti‐1,4‐bis[(4‐methyl‐5‐thien‐2‐yl‐2‐oxo‐1,3‐oxazolidin‐3‐
yl)methyl]	 piperazine,	 5e:	 Yield:	 56	 %.	 M.p.:	 145‐147	 °C	
(Decomp.).	 Rf	 =	 0.65,	 mobile	 phase:	 bezene:diethyl	 ether:	
ethanol	(4:1:3),	Al2O3‐plates.	1H	NMR	(CDCl3):	1.37	(6H,	CH3,	d,	
J=6.11	 Hz),	 2.45–2.67	 (8H,	 4	 NCH2,	 m,	 piperazine),	 3.85	 (2H,	
N(HCH)N,	 N(HCH)N,	 d,	 J=12.47	 Hz),	 3.99	 (2H,	 two	 N‐CH,	 m,	
from	 two	 oxazolidinone	 rings),	 4.16	 (2H,	N(HCH)N,	N(HCH)N,	
d,	J=12.47	Hz),	5.19	(2H,	two	OCH,	d,	J=7.34	Hz),	7.02	(2H,	SCH‐
CH‐CH,	 dd,	 J=3.42	 Hz,	 J=4.89	 Hz,	 from	 two	 thiophene	 rings),	
7.14	 (2H,	 SCH‐CH‐CH,	 dd,	 J=3.42	 Hz,	 J=1.22	 Hz	 from	 two	
thiophene	rings),	7.37	(2H,	SCH,	dd,	J=1.22,	J=4.89	Hz	from	two	
thiophene	 rings).	 13C	 NMR	 (CDCl3):	 17.3	 (CH3),	 50.2	 (NCH2,	
piperazine),	 58.6	 (NCH,	 oxazolidinone),	 63.9	 (NCH2N),	 78.4	
(OCH),	 126.7,	 126.	 8,	 127.0	 (CH,	 thiophene),	 140.0	 (C,	
thiophene),	157.1	(C=O).	Anal.	Calcd.	for	C22H28N4O4S2:	C,	56.30;	
H,	 6.16;	N,	 11.42;	 S,	 13.07;	 Found:	 56.23;	H,	 6.19;	N,	11.37;	 S,	
13.11.	
Syn‐1,4‐bis[(4‐methyl‐5‐thien‐2‐yl‐2‐oxo‐1,3‐oxazolidin‐3‐
yl)methyl]	 piperazine,	 7e:	 Yield:	 62	 %.	 M.p.:	 196‐197	 °C	
(Decomp.).	 Rf	 =	 0.48,	 mobile	 phase:	 benzene:diethyl	 ether:	
ethanol	(4:1:3),	Al2O3‐plates.	1H	NMR	(CDCl3):	0.97	(6H,	2	CH3,	
d,	 J=6.60	 Hz);	 2.59	 (8H,	 4	 N‐CH2,	 m,	 piperazine),	 3.81	 (2H,	
N(HCH)N,	 N(HCH)N,	 d,	 J=12.62	 Hz),	 4.23	 (4H,	 N(HCH)N,	
N(HCH)N,	d,	J=12.62	Hz;	overlapped	with	two	N‐CH,	dq,	J=8.07	
Hz,	J=6.60	Hz	from	the	two	oxazolidinone	rings),	5.82	(2H,	two	
OCH,	d,	J=8.07	Hz),	7.11–6.99	(4H,	2	SCH‐CH‐CH	and	2	SCH‐CH‐
CH,	m,	from	two	thiophene	rings),	7.33	(2H,	2	SCH,	m,	from	two	
thiophene	 rings).	 13C	 NMR	 (CDCl3):	 13.8	 (CH3),	 50.2	 (NCH2,	
piperazine),	 54.9	 (NCH,	 oxazolidinone),	 64.0	 (NCH2N),	 75.8	
(OCH),	 125.9,	 126.20,	 126.8	 (CH,	 thiophene),	 137.4	 (C,	
thiophene),	 159.4	 (C=O).	 Anal.	 Calcd.	 for	 C22H28N4O4S2:	 	 	 C,	
56.30;	 H,	 6.16;	 N,	 11.42;	 S,	 13.07;	 Found:	 56.35;	 H,	 6.11;	 N,	
11.47;	S,	13.0.	
	
2.3.	General	procedure	for	compounds	5a‐d	and	7a‐d	
	
A	one	necked	 flask	equipped	with	a	stirrer	and	condenser	
was	charged	with	1.2	g	(6.6	mmol)	of	anti‐4‐methyl‐5‐thien‐2‐
yl‐1,3‐oxazolidine‐2‐one	 4,	 respectively,	 the	 syn‐isomer	 6,	 50	
mL	ethanol,	0.46	mL	(5.3	mmol)	of	the	appropriate	amine	and	
0.7	mL	(9	mmol)	formaldehyde	in	form	of	35%	formalin.	After	
refluxing	 for	 2	 hours,	 the	 solvent	 was	 removed	 by	 reduced	
pressure	 and	 the	 remaining	 light	 yellow	 oil	 crystallized	 after	
cooling.	
Anti‐4‐methyl‐3‐(morpholin‐1‐ylmethyl)‐5‐thien‐2‐yl‐1,3‐
oxazolidin‐2‐one,	 5a:	 After	 removing	 of	 the	 solvent	 to	 the	
remaining	oil	 diethyl	 ether	was	added	and	 compound	5a	was	
crystallized.	 	 Re‐crystallization	 was	 carried	 out	 with	 ethanol.	
Yield:	 62	 %.	 M.p.:	 166‐169	 °C	 (Decomp.).	 Rf	 =	 0.61,	 mobile	
phase:	benzene:diethyl	ether:ethanol	 (4:1:2),	Silica	gel	F254.	 1H	
NMR(CDCl3):	 1.38	 (3H,	 CH3,	 d,	 J=6.24	 Hz),	 3.1–3.3	 (4H,	 2	
NCH2,m,	 morpholine),	 3.8–4.0	 (4H,	 2	 OCH2,	 m,	 morpholine),	
4.43–4.56	 (1H,	 NCH,	 m,	 oxazolidinone),	 4.58	 (1H,	 NHCHN,	 d,	
J=13.45	Hz),	4.72	(1H,	NHCHN,	d,	J=13.45	Hz),	5.55	(1H,	OCH,	d,	
J=6.66	Hz),	7.10	(1H,	SCH‐CH‐CH,	dd,	J=3.55	Hz,	J=5.01	Hz),	7.39	
(1H,	 SCH‐CH‐CH,	 dd,	 J=3.55	Hz,	 J=1.22	Hz),	 7.67	 (1H,	 SCH,	dd,	
J=1.22	Hz,	J=5.01	Hz).	13C	NMR	(CDCl3):	17.0	(CH3),	43.0	(NCH2,	
morpholine),	 49.1	 (NCH2,	 morpholine),	 58.4	 (NCH,	 oxazolidin	
one),	 61.2	 (NCH2N),	 63.1	 (OCH2,	 morpholine),	 63.6	 (OCH2,	
morpholine),	 78.4	 (OCH),	127.7,	 128.4,	 128.5	 (CH,	 thiophene),	
139.2	(C,	thiophene),	156.5	(C=O).	Anal.	Calcd.	for	C13H18N2O3S:	
C,	55.30;	H,	6.43;	N,	9.92;	S,	11.37;	Found:	C,	55.24;	H,	6.48;	N,	
9.86;	S,	11.43.	
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Syn‐4‐methyl‐3‐(morpholin‐1‐ylmethyl)‐5‐thien‐2‐yl‐1,3‐
oxazolidin‐2‐one,	7a:	After	 removing	 the	 solvent,	diethyl	ether	
was	 added	 and	 the	 compound	 crystallized.	 Recrystallization	
was	carried	out	with	ethanol.	Yield:	64	%.	M.p.:	83‐85	°C.	Rf	 =	
0.61,	mobile	phase:	benzene:diethyl	ether:ethanol	(4:1:2),	Silica	
gel	F254.	1H	NMR	(CDCl3):	0.98	(3H,	CH3,	d,	J=6.60	Hz),	2.69–2.49	
(4H,	 2	 NCH2,	 m,	 morpholine),	 3.75–3.66	 (4H,	 2	 OCH2,	 m,	
morpholine),	 3.79	 (1H,	 N(HCH)N,	 d,	 J=12.47	 Hz),	 4.21	 (1H,	
N(HCH)N,	d,	 J=12.47	Hz),	4.25	(1H,	NCH,	dq,	 J=8.07	Hz,	 J=6.60	
Hz),	 5.82	 (1H,	 OCH,	 d,	 J=8.07	 Hz),	 7.07–6.99	 (2H,	 two	 CH,	m,	
thiophene),	7.34	(1H,	SCH,	dd,	J=2.20	Hz,	J=4.16	Hz,	thiophene).	
13C	 NMR	 (CDCl3):	 13.8	 (CH3),	 50.9	 (NCH2,	 morpholine),	 54.9	
(NCH,	oxazolidinone),	64.4	(NCH2N),	66.7	(OCH2,	morpholine),	
75.8	 (OCH),	 125.9,	 126.2,	 126.8	 (CH,	 thiophene),	 137.4	 (C,	
thiophene),	157.4	(C=O).	Anal.	Calcd.	 for	C13H18N2O3S	C,	55.30;	
H,	 6.43;	N,	9.92;	 S,	 11.37;	 Found:	 C,	 55.35;	H,	 6.37;	N,	 9.85;	 S,	
11.29.	
Anti‐1‐{[4‐methyl‐2‐oxo‐5‐thien‐2‐yl‐1,3‐oxazolidin‐3‐
yl]methyl}piperidinium	chloride,	5b:	After	removing	ethanol	and	
water	under	reduced	pressure	dry	diethyl	ether	was	added	to	
the	 oil	 residue.	 Saturating	 ether	 solution	 with	 dry	 HCl	 gas	
resulted	in	the	formation	of	hydrogen	chloride	of	the	Mannich	
base.	 Yield	 68	 %,	 recrystallization	 with	 ether:ethanol	 (2:1).	
M.p.:	 156‐158	 °C.	 Rf	 =	 0.5,	 mobile	 phase	 benzene:diethyl	
ether:ethanol	 (4:1:3),	 Silica	 gel	 F254.	 1H	NMR	 (DMSO‐d6):	 1.38	
(3H,	 CH3,	 d,	 J=6.60	Hz),	 1.60‐1.98	 (6H,	m,	 3	 CH2	 ,	 piperidine),	
2.68‐3.10	 (2H,	 m,	 NCH2,	 piperidine),	 3.17‐3.48	 (2H,	 m,	 NCH2,	
piperidine),	 4.43‐4.67	 (3H,	 m,	 NCH2N,	 overlapped	 with	 NCH	
from	 oxazolidinone),	 5.56	 (1H,	 OCH,	 d,	 J=6.11	 Hz,	 oxazolidin	
one),	7.10	(1H,	SCH‐CH‐CH,	dd,	J=3.42	Hz,	J=5.14	Hz),	7.41	(1H,	
SCH‐CH‐CH,	dd,	J=3.42	Hz,	J=1.22	Hz),	7.68	(1H,	SCH,	dd,	J=1.22	
Hz,	 J=5.14	Hz),	 11.29	 (1H,	NH,	bs).	 13C	NMR	 (	DMSO‐d6):	 16.7	
(CH3),	 21.4	 (CH2,	 piperidine),	 21.7	 (CH2,	 piperidine),	 48.9	
(NCH2,	 piperidine),	 49.9	 (NCH2,	 piperidine),	 57.8	 (NCH,	
oxazolidinone),	 60.5	 (NCH2N),	 77.8	 (OCH,	 oxazolidinone),	
127.2,	 127.8,	 128.0	 (CH,	 thiophene).	 Anal.	 Calcd.	 for	
C14H21ClN2O2S:	 C,	 53.07;	 H,	 6.68;	 Cl,	 11.19;	 N,	 8.84;	 S,	 10.12;	
Found:	C,	53.11;	H,	6.62;	Cl,	11.26;	N,	8.78;	S,	10.17.	
Syn‐1‐{[(4‐methyl‐2‐oxo‐5‐thien‐2‐yl‐1,3‐oxazolidin‐3‐
yl]methyl}piperidinium	chloride,	7b:	After	removing	ethanol	and	
water	under	reduced	pressure	dry	diethyl	ether	was	added	to	
the	 oil	 residue.	 Saturating	 of	 ether	 solution	with	 dry	 HCl	 gas	
resulted	to	the	formation	of	hydrogen	chloride	of	Mannich	base.	
Yield	 68	 %,	 after	 recrystallization	 with	 ether:ethanol	 (2:1).	
M.p.:	 181‐182	 °C.	 Rf	 =	 0.68,	 mobile	 phase	 benzene:diethyl	
ether:ethanol	 (4:1:3),	 Silica	 gel	 F254.	 1H	NMR	 (DMSO‐d6):	 0.93	
(3H,	 CH3,	 d,	 J=6.60	 Hz),	 1.62‐1.96	 (6H,	 m,	 3	 CH2	 from	
piperidine),	2.67‐3.11	(2H,	m,	NCH2,	piperidine),	3.31‐3.58	(2H,	
m,	 NCH2,	 piperidine),	 4.42‐4.54	 (1H,	 NHCHN,	 d,	 J=13.45	 Hz),	
4.54‐4.80	 (2H,	 m,	 NHCHN	 overlapped	 with	 NCH	 from	
oxazolidinone),	6.18	(1H,	OCH,	d,	J=7.58	Hz),	7.11	(1H,	SCH‐CH‐
CH,	dd,	J=3.55	Hz,	J=5.14	Hz),	7.18	(1H,	SCH‐CH‐CH,	dd,	J=3.42	
Hz,	 J=1.22	Hz),	7.63	(1H,	SCH,	dd,	J=1.22	Hz,	 J=5.14	Hz),	11.29	
(1H,	 NH,	 bs).	 13C	 NMR	 (DMSO‐d6):	 13.7	 (CH3),	 22.0	 (CH2,	
piperidine),	 22.1	 (CH2,	 piperidine),	 49.6	 (NCH2,	 piperidine),	
51.5	 (NCH2,	 piperidine),	 55.9	 (NCH,	 oxazolidinone),	 61.6	
(NCH2N),	 77.0	 (OCH,	 oxazolidinone),	 126.2,	 126.6,	 127.0	 (CH,	
thiophene),	135.7	(C,	thiophene),	157.4	(C=O).	 	Anal.	Calcd.	for	
C14H21ClN2O2S:	 C,	 53.07;	 H,	 6.68;	 Cl,	 11.19;	 N,	 8.84;	 S,	 10.12;	
Found:	C,	53.01;	H,	6.74;	Cl,	11.13;	N,	8.77;	S,	10.05.	
Anti‐3‐{[4‐(4‐chlorophenyl)piperazin‐1‐yl]methyl}‐4‐methyl‐
5‐thien‐2‐yl‐1,3‐oxazolidin‐2‐one,	5c:	Yield	67	%.	M.p.:	130‐131	
°C,	 re‐crystallization	 with	 ethanol.	 Rf	 =	 0.54,	 mobile	 phase:	
benzene:diethyl	 ether	 (4:1),	 Silica	 gel	 F254.	 1H	 NMR	 (CDCl3):	
1.39	 (d,	 3H,	 CH3,	 J=6.2	Hz);	 2.72	 (m,	 4H,	 2	NCH2,	 piperazine);	
3.15	(m,	4H,	2	NCH2,	piperazine);	3.91	(d,	1H,	N(HCH)N,	J=12.6	
Hz);	 4.03	 (m,	 1H,	NCH,	 qd,	 J=6.2	Hz,	 J=7.2	Hz,	 oxazolidinone);	
4.24	 (d,	 1H,	N(HCH)N,	 J=12.6	Hz);	 5.20	 (d,	 1H,	 CHO,	 J=7.2	Hz,	
oxazolidinone);	 6.83	 (m,	 2H,	 CH‐Ph,	AA’BB’	 system);	 7.02	 (dd,	
1H,	 SCH‐CH‐CH,	 J=5.1	 Hz,	 J=3.7	 Hz,	 thiophene);	 7.14	 (1H,	 dd,	
J=1.2	Hz,	J=3.7	Hz,	SCH‐CH‐CH,	thiophene),	7.20	(m,	2H,	CH‐Ph,	
AA’BB’	 system);	 7.37	 (dd,	 1H,	 SCH,	 J=1.2	 Hz,	 J=5.1	 Hz,	
thiophene).	13C	NMR	(CDCl3):	17.3	(CH3),	48.9,	50.3,	58.7,	63.8,	
78.5,	117.3	(CH,	Ph),	124.6	(C,	Ph),	126.8	(CH,	thiophene),	126.8	
(CH,	 thiophene),	 127.0	 (CH,	 thiophene),	 128.9	 (CH,	 Ph),	 139.9	
(C,	 thiophene),	 149.7	 (C,	 Ph),	 157.1	 (C=O).	 Anal.	 Calcd.	 for	
C19H22ClN3O2S:	 	 C,	 62.95;	 H,	 6.16;	 N,	 12.23;	 S,	 9.34;	 Found:	 C,	
62.87;	H,	6.12;	N,	12.28;	S,	9.40.	
Syn‐3‐{[4‐(4‐chlorophenyl)piperazin‐1‐yl]methyl}‐4‐methyl‐
5‐thien‐2‐yl‐1,3‐oxazolidin‐2‐one,	7c:	Yield	64	%.	M.p.:	118‐120	
°C,	 recrystallization	 with	 ethanol.	 Rf	 =	 0.48,	 mobile	 phase:	
benzene:diethyl	ether	(4:1),	Silica	gel	F254.	1H	NMR	(CDCl3):	1.02	
(d,	 3H,	 CH3,	 J=6.60	Hz);	 2.75	 (m,	 4H,	 2	NCH2,	 piperazin);	 3.16	
(m,	4H,	2	NCH2);	3.88	(1H,	d,	N(HCH)N,	J=12.72	Hz);	4.29	(2H,	
N(HCH)N,	 d,	 J=12.72	 Hz,	 overlapped	 with	 NCH	 from	
oxazolidinone);	 5.83	 (1H,	 d,	 CHO,	 J=7.83	 Hz,	 oxazolidinone);	
6.84	(m,	2H,	CH‐Ph,	AA’BB’	system);	7.01‐7.06	(2H,	m,	SCH‐CH‐
CH	 and	 SCH‐CH‐CH,	 thiophene);	 7.17‐7.24	 (m,	 2H,	 CH‐Ph,	
AA’BB’	 system);	 7.33	 (1H,	 dd,	 SCH,	 J=2.20	 Hz,	 J=4.16	 Hz,	
thiophene).	Anal.	Calcd.	for	C19H22ClN3O2S:	C,	62.95;	H,	6.16;	N,	
12.23;	S,	9.34;	Found:	C,	62.89;	H,	6.20;	N,	12.16;	S,	9.38.	
Anti‐4‐methyl‐3‐[(4‐benzhydrylpiperazin‐1‐yl)methyl]‐5‐
thien‐2‐yl‐1,3‐oxazolidin‐2‐one,	5d:	Yield	70%.	M.p.:	133‐134	°C,	
recrystallization	 with	 ethanol.	 Rf	 =	 0.62,	 mobile	 phase:	
benzene:diethyl	 ether:ethanol	 (4:1:3),	 Silica	 gel	 F254.	 1H	 NMR	
(CDCl3):	 1.34	 (3H,	 CH3,	 d,	 J=6.06	Hz),	 2.22‐2.41	 (8H,	 4CH2,	m,	
piperazine),	3.71	(1H,	N(HCH)N,	d,	J=12.62	Hz),	4.16‐4.01	(3H,	
N(HCH)N,	 overlapped	 with	 CH(Ph)2	 	 and	 N‐CH	 from	
oxazolidinone),	 5.19	 (1H,	 OCH,	 d,	 J=6.65	 Hz),	 7.42‐6.92	 (13H,	
2Ph	 and	 CH	 from	 thiophene).	 Anal.	 Calcd.	 for	 C26H29N3O2S:	 C,	
69.77;	H,	6.53;	N,	9.39;	S,	7.16;	Found:	C,	69.70;	H,	6.48;	N,	9.29;	
S,	7.22.	
Syn‐4‐methyl‐3‐[(4‐benzhydrylpiperazin‐1‐yl)methyl]‐5‐
thien‐2‐yl‐1,3‐oxazolidin‐2‐one,	7d:	Yield	65%.	M.p.:	163‐164	°C,	
recrystallization	 with	 ethanol.	 Rf	 =	 0.41,	 mobile	 phase:	
benzene:diethyl	 ether:ethanol	 (4:1:3),	 Silica	 gel	 F254.	 1H	 NMR	
(CDCl3):	 0.94	 (3H,	 CH3,	 d,	 J=6.46	Hz),	 2.61‐2.41	 (8H,	 4CH2,	m,	
piperazine),	 3.79	 (1H,	 N(HCH)N,	 d,	 J=12.62),	 4.27‐4.16	 (3H,	
N(HCH)N,	 overlapped	 with	 CH(Ph)2	 	 and	 N‐CH	 from	
oxazolidinone),	 5.79	 (1H,	 OCH,	 d,	 J=7.81	 Hz),	 7.42‐7.02	 (13H,	
2Ph	 and	3	 CH	 from	 thiophene).	 13C	NMR,	 (CDCl3):	 13.8	 (CH3),	
50.7	 (N‐CH2,	piperazine),	51.5	 (N‐CH2,	piperazine),	55.1	 (NCH,	
oxazolidinone),	 64.0	 (NCH2N),	 75.7	 (CH(Ph)2),	 76.0	 (OCH),	
125.8,	 126.1,	 126.8	 (CH,	 thiophene),	 126.9	 (para	 CH	 from	 Ph	
rings),	127.8	(ortho	CH	from	Ph	rings),	128.4	(meta	CH	from	Ph	
rings),	 137.5	 (C,	 thiophene),	 142.5	 (C	 form	 Ph	 rings),	 157.4	
(C=O).	Anal.	Calcd.	for	C26H29N3O2S:	C,	69.77;	H,	6.53;	N,	9.39;	S,	
7.16;	Found:	C,	69.69;	H,	6.60;	N,	9.34;	S,	7.19.	
	
3.	Results	and	discussion	
	
The	Mannich	 bases	 of	 syn	 and	 anti‐4‐methyl‐5‐thien‐2‐yl‐
1,3‐oxazolidin‐2‐ones	were	 thesized	 as	 depicted	 in	 Scheme	 1.	
The	 starting	 (2S,3R)	 and	 (2R,3R)‐3‐hydroxy‐2‐methyl‐3‐thien‐
2‐ylpropanohydrazides	2	and	3	were	prepared	in	ethanol	using	
hydrazine	 hydrate	 	 and	 the	 diastereoisomeric	mixture	 of	 (2R,	
3R)	and	 (2S,3R)‐ethyl	3‐hydroxy‐2‐methyl‐3‐thien‐2‐ylpropan‐
oate	1,	obtained	through	the	Reformatsky	reaction.	The	(2S,3R)	
and	 (2R,3R)‐3‐hydroxy‐2‐methyl‐3‐thien‐2‐ylpropano‐hydrazi‐
des	were	separated	as	we	described	early	[22].	
The	 treatment	 of	 the	 corresponding	 (2S,3R)	 or	 (2R,5R)‐3‐
hydroxy‐2‐methyl‐3‐thien‐2‐ylpropano‐hydrazides	 with	 water	
solution	of	sodium	nitrite	 in	acetic	acid/diethyl	ether	medium	
via	 	 β‐hydroxy‐azides	 at	 15‐20	 °C	 and	 	 followed	 by	 Curtius	
rearrangement	 of	 β‐hydroxy‐isocyanates	 at	 refluxing	 of	 the	
separated	organic	solution	led	to	forming	the	1,3‐oxazolidin‐2‐
one	cycle	4	or	6.	
The	 oxazolidin‐2‐one	 4	 or	 6,	 morpholine,	 piperidine,	
benzhydrylpiperazine	 and	 35%	 formalin	 were	 used	 in	 the	
Mannich	reaction	in	ratio	1:0.8:1.3	and	by	the	use	of	piperazine	
the	ratio	was	2:1:2.5.	The	process	was	carried	out	by	refluxing	
in	ethanol	for	2‐3	hours.	
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Scheme	1	
	
It	is	known	that	the	nucleophilic	properties	of	the	reagents	
participating	 in	 the	 Mannich	 reaction	 are	 of	 a	 significant	
importance	 for	 the	 successful	 performing	 of	 the	 synthesis.	 It	
was	 estimated	 that	 by	 the	 reaction	 between	 anti‐	 and	 syn‐4‐
methyl‐5‐thien‐2‐yl‐1,3‐oxazolidin‐2‐ones	 and	 the	 above	
mentioned	 secondary	 cyclic	 amines	 it	 is	 enough	 to	 use	 a	 low	
access	 of	 the	 amines	 to	 complete	 the	 synthesis	 	 successfully.	
Because	 the	 asymmetrical	 centers	 were	 not	 involved	 in	 the	
reaction,	the	C‐atoms	at	4th	and	5th	position	of	oxazolidin‐2‐one	
cycle	 in	 the	 corresponding	 compounds	 5a‐e	 and	 7a‐e	
preserved	 the	 same	 configuration	 as	 these	 in	 the	 starting	
oxazolidin‐2‐ones.	Some	physical	data	are	given	in	Table	1.	
In	 order	 to	 determine,	 the	 geometry	 and	 the	 dihedral	
angels	 of	 compounds	 4	 and	 6,	 DFT	 computations	 were	
performed	 with	 standard	 Gaussian	 98	 program	 package.	 We	
employed	 the	 B3LYP	 hybrid	 functional	 with	 6‐31G	 basis	 set.	
Furthermore	for	the	calculation	of	some	steric,	physicochemical	
and	 electronic	 parameters	 of	 compounds	 5a‐e	 and	 7a‐e	
Chem3D	Ultra,	ChemDraw	Ultra,	Version	11.0.1	was	used	[23].	
Structures	of	the	compounds	were	confirmed	by	1H	and	13C	
NMR	spectra.	The	stereochemistry	of	anti‐	and	syn‐isomers	was	
assigned	using	 the	observed	differences	 in	 the	 chemical	 shifts	
of	some	key	signals	and	the	values	of	vicinal	coupling	constants	
(3J)	 between	 the	 two	 protons	 from	 the	 oxazolidin‐2‐one	 ring.	
For	 all	 compounds	 NOE	 (Nuclear	 Overhauser	 Effect)	 NMR	
spectra	 were	 measured	 in	 order	 to	 prove	 additionally	 the	
position	of	the	substituents	in	the	oxazolidin‐2‐one	ring.	
In	five	membered	rings,	due	to	their	higher	conformational	
flexibility,	the	dihedral	angles	()	are	less	well	defined	and	the	
vicinal	coupling	constants	are	not	characteristic	in	general.	The	
conformation	of	 oxazolidinone	 ring	 in	 the	 studied	 compounds	
is	relatively	fixed	due	to	the	presence	of	two	bulky	substituents	
at	C4	and	C5	atoms.	The	theoretical	values	of	the	dihedral	angle	
defined	by	H5‐C5‐C4‐H4	atoms	of	the	oxazolidinone	ring	in	the	
optimized	 structures	 of	 the	 studied	 compounds	 are	 between	
3.4	 and	 17.3	 degrees	 for	 syn‐isomers	 and	 between	 124.2	 and	
140.3	 degrees	 for	 anti‐compounds,	 depending	 on	 the	
substituents.	 The	 experimental	 3J	 constants	 of	 syn‐derivatives	
are	 systematically	 higher	 as	 compared	 with	 those	 in	 the	
respective	 anti‐compounds.	 The	 experimental	 3J	 constant	 for	
syn‐isomers	 was	 found	 to	 be	 7.88	 Hz,	 averaged	 over	 six	
compounds,	while	for	the	trans‐derivatives	the	value	is	6.77	Hz	
averaged	 over	 five	 compounds.	 These	 results	 follow	 the	
tendency	and	are	 in	a	very	good	agreement	with	 the	 3J	values	
theoretically	 predicted	 by	 Karplus	 curve	 simulated	 using	 the	
Karplus	 equation	 with	 coefficients	 applicable	 for	 H‐C‐C‐H	
fragments	and	above	given	values	of	the	dihedral	angles	[24].	
The	 chemical	 shift	 values	 for	 the	 methyl	 protons	 in	 anti‐
compounds	 are	 systematically	 higher	 (av.	 value	 1.38	 ppm)	 as	
compared	with	those	for	the	respective	syn‐	isomers	(av.	value	
0.97	ppm).	The	differences	(CH3)	=	 [(CH3‐anti)	–	(CH3‐syn)],	
for	 a	 given	 diastereomeric	 pair	 are	 in	 the	 range	 0.45	 –	 0.40	
ppm.	Figure	1	represents	the	1H	spectra	of	the	two	isomers	7b	
and	5b.	
	
Figure	1.	1H	NMR	spectra	of	the	two	isomers:	(a)	7b	(syn)	and	(b)	5b	(anti).	
	
This	 observation	 could	 be	 explained	 by	 the	 magnetic	
anisotropy	effect	of	the	double	bonds	from	the	thiophen	ring.	In	
syn‐compounds	 the	 CH3	 group	 is	 oriented	 parallel	 to	 the	
thiophen	 ring	 and	 the	 protons	 are	 in	 the	 vicinity	 of	 the	
shielding	 zone	 above	 the	 double	 bonds	 plane.	 Another	
characteristic	signal	is	the	one	for	OCH	from	the	oxazolidinone	
ring,	which	 is	 systematically	 deshielded	 in	 syn‐compounds	 by	
0.52	ppm	in	average	–	see	Figure	1	as	an	example.	This	finding	
is	 attributed	 to	 the	 ‐effect,	 which	 in	 CH3–C–C–H	 molecular	
fragments	leads	to	downfield	shift	if	the	proton	and	the	methyl	
group	 are	 in	 antiperiplanar	 position,	 as	 in	 the	 case	 of	 syn‐
isomers,	and	to	upfield	shift	if	the	proton	is	in	syn	position	with	
respect	to	methyl	group	as	in	the	case	of	anti‐isomers.	
The	 above	 conclusions	 were	 based	 on	 general	
considerations	of	different	factors	that	influence	chemical	shifts	
and	coupling	constants	and	were	made	by	comparison	of	these	
NMR	 parameters	 for	 the	 two	 isomers.	 To	 give	 another	
independent	 evidence	 for	 the	 structure	 of	 the	 diastereomeric	
pairs	 and	 to	 additionally	 prove	 their	 stereochemistry	 we	
measured	 the	 NOE	 enhancements	 observed	 in	 the	 NOE	
difference	spectra	after	the	irradiation	of	some	key	signals.	
NOE	gives	information	about	molecular	fragments	that	are	
in	 space	 proximity	 and	 is	 an	 effective	 method	 to	 study	 the	
relative	arrangement	of	different	molecular	fragments,	e.g.	the	
stereochemistry	[25].	
Figure	 2	 represents	 the	 optimized	 structures	 of	 the	 two	
isomers	 with	 some	 key	 NOE	 contacts	 indicated	 with	 arrows.	
For	all	syn‐compounds	(6,	7a,	7b,	7c,	7d,	7e)	the	irradiation	of	
the	OCH	proton	from	the	oxazolidinone	ring	gives	a	very	strong	
NOE	of	 the	 signal	 for	 the	CH‐4	proton	 from	 the	oxazolidinone	
ring.	The	irradiation	of	the	CH3	group	leads	to	NOE	for	the	CH‐4	
proton		attached		to		the		same		carbon		atom		and		for	one	of	the	
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Table	1.	Yields	and	physical	data	of	the	synthesized	compounds.	
Compound	 Configuration	 X	 Yield	(%) M.p.	(°C) Formula
4	 anti	 ‐	 70.0 87‐90 C8H9NO2S
5a	 anti	 O	 62.0 166‐169 C13H18N2O3S
5b	 anti	 CH2	 68.0 156‐158 C14H21ClN2O2S
5c	 anti	 N‐(4‐Cl‐Ph)	 67.0 130‐131 C19H22ClN3O2S
5d	 anti	 N‐CH(C6H5)2	 70.0 133‐134 C26H29N3O2S
5e	 anti	
 
56.0	 145‐147	(Decomp.)	 C22H28N4O4S2	
6	 syn	 ‐	 65.0 101‐102 C8H9NO2S
7a	 syn	 O	 64.0 83‐85 C13H18N2O3S:
7b	 syn	 CH2	 68.0 181‐182 C14H21ClN2O2S
7c	 syn	 N‐(4‐Cl‐Ph)	 64.0 118‐120 C19H22ClN3O2S
7d	 syn	 N‐CH(C6H5)2	 65.0 163‐165 C26H29N3O2S
7e	 syn	
 
62.0	 196‐197	(Decomp.)	 C22H28N4O4S2	
	
	
thiophene	protons,	 however	no	NOE	 is	observed	 for	 the	OCH.	
These	observations	imply	that	the	CH3	group	and	the	thiophene	
ring	are	in	syn‐orientation.	For	trans‐compounds	(4,	5a,	5b,	5c,	
5d	and	5e)	 the	 irradiation	of	 the	proton	 from	OCH	gives	very	
strong	NOE	for	the	signal	of	 the	CH3	group,	while	no	effect	on	
the	other	proton	from	the	oxazolidin‐2‐one	ring	was	observed.	
An	 example	 of	 NOE’s	 observed	 for	 compounds	 5b	 and	 7b	 is	
presented	 on	 Figure	 3.	 All	 the	 NOE	 data	 obtained	 for	 the	
compounds	are	included	in	Tables	2	and	3.	
	
	
	
Figure	2.	Key	NOE	contacts	observed	for:	(a)	syn‐compounds	and	(b)	anti‐
compounds.	
	
Figure	 3.	NOE	 difference	 spectra	 of	 the	 two	 isomers:	 7	 b	 (syn)	 and	 5	 b	
(anti):	 (a)	 irradiation	of	OCH	proton	 from	oxazolidinone;	(b)	 irradiation	of	
CH3	group	in	position	4.	
	
In	the	case	of	drug	discovery,	the	likeness	in	the	structures	
of	compounds	is	a	widely	used	approach,	but	chemically	similar	
compounds	may	have	different	biological	actions	and	different	
molecules	 can	 have	 similar	 biological	 properties	 [27].	 The	
similarity	between	compounds	can	be	expressed	as	a	distance	
in	real	valued	descriptors	such	as	topological,	physicochemical	
or	 quantum	 chemical	 ones	 [28].	 The	 distance	 between	 two	
points	 can	 be	 a	 measure	 for	 the	 similarity	 between	 two	
compounds.	Therefore	the	distance	di	of	a	particular	compound	
“i”	to	the	model	compound	A	respectively	to	B	(Figure	4)	could	
be	calculated	according	to	equation	1	as	described	in	[29]:	
	 	
d i 
2 =
Xi,j
Xi,M

j=1
1 -
n
n
2
	 	 																																									(1)	
	
where	Xi,j		is	the	value	of	molecular	descriptor	“i”	for	compound	
“j”,	Xi,M	is	the	value	of	the	equivalent	descriptor	“i”	for	the	model	
compound	A	 respectively	 for	B	and	 “n”	 is	 the	 total	number	of			
the	 considered	 molecular	 parameters.	 Then	 the	 similarity	 of	
compound	 “j”	 to	 the	 refer	 compound	A	 (B)	 is	 to	be	 calculated	
according	to	equation	2:	
	
Similarity	(%)	=	(1‐R)	×	100				 	 																						(2)	
	
Where	R	=	√	d	 2	 is	 the	quadratic	mean	and	 is	 a	measure	of	 a	
central	tendency.	
	
Figure	4.	Reference	compounds	A	and	B.	
	
The	model	compounds	A	and	B	were	found	to	possess	analgesic	
activity	against	acetic	acid‐induced	pain.	Compound	A	revealed		
96	%		and	 	compound		B	 	98	%		activity,	but	their	LD50	values	
were	quite	different	‐	800	mg/kg	and	2000	mg/kg,	respectively	
[16].	 Therefore	 it	 is	 of	 interest	 to	 determine	 the	 similarity	
between	the	model	compounds	and	the	newly	synthesized,	and	
to	 compare	 their	 steric,	 electronic	 and	 physicochemical	
properties.	
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Table	2.	NOE	data	(%)	for	compounds	6	and	7a‐e.	
Irradiated	signal	
NOE	%	Compound
6	 7a 7b 7c 7d	 7e
OCH	 4.8	–	NCH	 3.3	– Th
6.2	–	NCH	
7.3	– Th
13	–	NCH	
4.5	– Th
8.7	–	NCH	
6.7	–	Th	
9.6	–	NCH	
4.5	– Th
9.4	–	NCH	
CH3	 3.2	–	NCH	 2.5	–	NCH	 3.7	–	NCH	 N.A.	 N.A.	
1.5	– Th
4.2	–	NCH	
N.A.:	not	available	
	
Table	3.	NOE	data	(%)	for	compounds	4	and	5a‐e.	
Irradiated	signal	
NOE	%	Compound
4	 5a 5b 5c 5d	 5e
OCH	 3.3	–	CH3	 3.6	–	CH3	 4.4	–	CH3	 3.5	–	CH3	 3.2	–	CH3	
3.3	– Th
3.9	–	CH3	
	
	
For	 the	 assessment	 of	 the	 similarity	 between	 the	
synthesized	compounds	and	reference	compounds	A	and	B,	we	
used	4	steric	molecular	surface	descriptors,	6	electronic	and	3	
physicochemical	 molecular	 parameters.	 The	 steric	 and	
molecular	surface	descriptors	are	as	follows:	
ClsC‐(Cluster	 Count)‐Topology	 Indice;	 ‐	 SAS	 (Connolly	
Solvent	Accessible	Surface	Area)	‐	Å2,	the	focus	of	the	center	of	
a	spherical	probe	(representing	the	solvent)	as	it	is	rolled	over	
the	molecular	model;	‐	MS	(Connolly	Molecular	Surface	Area)	‐	
Å2,	 	 the	 contact	 surface	 created	when	 a	 sphere	 (representing	
the	solvent)	is	rolled	over	the	molecular	model;	‐	SEV	(Connolly	
Solvent‐Excluded	 Volume)	 ‐	 Å	 3,	 the	 volume	 contained	within	
the	 contact	 molecular	 surface	 created	 when	 a	 sphere	
(representing	the	solvent)	is	rolled	over	the	molecular	model.	
The	 followed	 global	 physicochemical	 parameters	 were	
calculated:	 ‐	 log	 P	 (hydrophobic	 parameter	 ‐	 octanol‐water	
partition	coefficient);	 ‐	MR	 (Molar	refractivity)	 ‐	Kcal/mol;	 ‐	E	
(Total	energy)	‐	Kcal/mol.	
The	quantum	chemical	 descriptors	 used	by	determination	
of	 similarity	 were:	 ‐	 HOMO‐energy	 (The	 Highest	 Occupied	
Molecular	Orbital	 energy)	 ‐	 eV;	 ‐	LUMO	 ‐	 energy	 (The	Lowest	
Occupied	 Molecular	 Orbital	 energy)	 ‐	 eV;	 ‐	 ElcE	 (Electronic	
energy)	 ‐	 eV;	 ‐	 TotE	 (Total	 energy)	 ‐	 (eV);	 ‐DPL	 (Dipole)	 ‐	
(Debye);	‐	NRE	nucleus‐nucleus	repulse	energy	‐	(eV).	
After	 the	 computation	 of	 descriptors,	 it	 was	 established	
that	 the	 likeness	 between	 5d,	 respectively,	 7d	 and	 the	
reference	compounds		had	the	highest	value	‐	90.53	and	94.53	
%,	followed	by	5e	‐	80.4	and	7e		86.01	as	well	as	by	5c	and	7c		
80.54	and	76.30	%	respectively,	as	it	can	be	seen	from	the	data	
given	in	Table	4.	
The	 values	 of	 the	 descriptors	 and	 the	 calculation	 of	
Equation	1	for	compound	5d	are	as	follows:	
	
d2	=	[(1‐ClC5d/ClCA)	2	+	(1	‐	SAS	5d/	SAS	A)	2	+	(1‐	MS	5d/	MS	A)	2	+	
(1	‐	SEV5d/	SEV	A)	2	+	(1	‐	DPL	
5d/	DPL	A)	2	+	(1	‐	ElcE5d/ElcE	A)	2	+	(1‐	HOMO5d/HOMOA)	2	+	(1‐	
LUMO5d/LUMOA)	2	+	(1	‐	LogP5d/	LogP	A)	2	+	(1	‐	MR5d/	MR	A)	2	+	
(1‐	E5d/	E	A)	2	+	(1‐	NRE5d/	NRE	A)	2	+	(1‐	TotE5d/TotEA)	2]/13	=	
	[(1‐32/33)2	+	(1‐	629.609/646.879)2	+	(1	‐	410.135/425.959)2	
+	 (1	 ‐	 383.254/401.380)2	 +	 (1‐	 5.2213/4.4871)2	 +	 (1	 ‐	
45972.9/49035.5)2	+	(1	‐	9.19889/8.99577)2	+	(1	‐	0.143672/	
0.112407)2	+	 (1	 ‐	5.346/5.682)2	+	 (1	 ‐	129.21/134.32)2	+	 (1	 ‐	
129.338/127.465)2	 +	 (1	 ‐	 40790.9/43697.8)2	 +	 (1	 ‐	
5182/5338)2]/13	=	0.09473	
	
Because	 the	 frontier	molecular	 orbital	 are	 involved	 in	 the	
activity	 properties	 of	 the	 compounds,	 the	 highest	 occupied	
molecular	 orbital	 (HOMO)	 energy	 and	 the	 lowest	 unoccupied	
molecular	 orbital	 (LUMO)	 energy	 is	 discussed.	 The	 HOMO	
energy	relates	to	the	ionization	potential	and	the	reactivity	of	a	
molecule	 as	 a	 nucleophile.	 The	 LUMO	 energy	 represents	 the	
electron	 affinity	 of	 a	 molecule	 or	 its	 reactivity	 as	 an	
electrophile.The	 performed	 computation	 showed	 lower	
electronic	energies	(ElcE)	of	the	anti‐isomers	in	comparison	to	
those	of	 the	syn‐diastereoisomers,	but	 regarding	 to	 the	HOMO	
energies	 and	 the	 repulse	 energies	 (NRE),	 the	 anti‐isomers	
possessed	higher	values	than	syn‐diastereoisomers.	If	the	steric	
descriptors	are	taken	in	consideration	it	is	pointed	out	that	the	
SAS	and	MS	values	of	anti‐isomers	are	lower	than	these	of	syn‐
isomers.	The	same	relations	are	observed	for	compound	A	and	
compound	 B.	 Probably,	 the	 differences	 in	 the	 steric	 and	
electronic	properties	of	the	compounds	are	responsible	for	the	
different	 LD50	 values	 of	 the	 both	 isomers.	 It	may	 be	 expected	
that	 the	 new	 synthesized	 compounds	 would	 act	 in	 a	 similar	
way.	 The	 biological	 study	 of	 the	 reported	 compounds	 is	 in	
progress.	
	
Table	 4.	 Calculated	 value	 of	 the	 distances	 and	 the	 similarity	 of	 the	
compounds.	
Compound d2 R	 Similarity%
5a 0.1587 0.3983							 61.16	
7a 0.1788 0.4229	 57,71	
5b 0,1331 0.3649			 63,51	
7b 0,3581 0.3581	 64,19	
5c 0,0379 0.1946													 80,54	
7c 0,0562 0.2370	 76.30	
5d 0,0090 0.0947	 90.53	
7d 0,0030 0.0547			 94.53	
5e 0,0399 0.1996	 80.04	
7e 0,0196 0.1399	 86.01	
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